nodes	percent_of_prediction	percent_of_DWPC	metapath
Celecoxib—CA9—kidney cancer	0.198	0.458	CbGaD
Celecoxib—CA2—kidney cancer	0.178	0.412	CbGaD
Celecoxib—PTGS2—kidney cancer	0.0558	0.129	CbGaD
Celecoxib—ORM1—Erlotinib—kidney cancer	0.035	0.141	CbGbCtD
Celecoxib—ABCC4—Sorafenib—kidney cancer	0.0323	0.13	CbGbCtD
Celecoxib—ABCC4—Sunitinib—kidney cancer	0.0262	0.106	CbGbCtD
Celecoxib—CYP2D6—Temsirolimus—kidney cancer	0.0194	0.0781	CbGbCtD
Celecoxib—CYP3A4—Everolimus—kidney cancer	0.0182	0.0735	CbGbCtD
Celecoxib—ALB—Erlotinib—kidney cancer	0.0147	0.0594	CbGbCtD
Celecoxib—CYP3A4—Temsirolimus—kidney cancer	0.0123	0.0497	CbGbCtD
Celecoxib—CYP2C9—Capecitabine—kidney cancer	0.0116	0.0468	CbGbCtD
Celecoxib—CYP2D6—Pazopanib—kidney cancer	0.0102	0.041	CbGbCtD
Celecoxib—CYP2C9—Paclitaxel—kidney cancer	0.00727	0.0293	CbGbCtD
Celecoxib—CYP2D6—Erlotinib—kidney cancer	0.00726	0.0293	CbGbCtD
Celecoxib—CYP3A4—Pazopanib—kidney cancer	0.00647	0.0261	CbGbCtD
Celecoxib—CYP2C9—Sorafenib—kidney cancer	0.00646	0.026	CbGbCtD
Celecoxib—CYP2D6—Sorafenib—kidney cancer	0.0059	0.0238	CbGbCtD
Celecoxib—CYP2D6—Vinblastine—kidney cancer	0.00583	0.0235	CbGbCtD
Celecoxib—CA2—collecting duct of renal tubule—kidney cancer	0.00483	0.148	CbGeAlD
Celecoxib—CYP3A4—Erlotinib—kidney cancer	0.00462	0.0186	CbGbCtD
Celecoxib—CYP3A4—Paclitaxel—kidney cancer	0.00423	0.017	CbGbCtD
Celecoxib—CYP3A4—Sorafenib—kidney cancer	0.00375	0.0151	CbGbCtD
Celecoxib—CYP3A4—Vinblastine—kidney cancer	0.00371	0.0149	CbGbCtD
Celecoxib—CYP3A4—Vincristine—kidney cancer	0.00364	0.0147	CbGbCtD
Celecoxib—CYP2D6—Doxorubicin—kidney cancer	0.00358	0.0144	CbGbCtD
Celecoxib—CYP3A4—Sunitinib—kidney cancer	0.00304	0.0123	CbGbCtD
Celecoxib—CYP3A4—Doxorubicin—kidney cancer	0.00228	0.00919	CbGbCtD
Celecoxib—PDPK1—nephron tubule—kidney cancer	0.00223	0.0684	CbGeAlD
Celecoxib—PDPK1—renal system—kidney cancer	0.00202	0.0622	CbGeAlD
Celecoxib—PDPK1—kidney—kidney cancer	0.00196	0.0601	CbGeAlD
Celecoxib—PDPK1—gonad—kidney cancer	0.00182	0.0557	CbGeAlD
Celecoxib—PTGS2—nephron—kidney cancer	0.00159	0.0487	CbGeAlD
Celecoxib—CYP2C9—urine—kidney cancer	0.00146	0.0448	CbGeAlD
Celecoxib—CYP3A4—urine—kidney cancer	0.00111	0.0341	CbGeAlD
Celecoxib—CYP2D6—urine—kidney cancer	0.00109	0.0336	CbGeAlD
Celecoxib—MAPK14—renal system—kidney cancer	0.00108	0.0332	CbGeAlD
Celecoxib—MAPK14—kidney—kidney cancer	0.00105	0.0321	CbGeAlD
Celecoxib—CA14—cardiac atrium—kidney cancer	0.000943	0.029	CbGeAlD
Celecoxib—CA12—renal system—kidney cancer	0.000821	0.0252	CbGeAlD
Celecoxib—CA12—kidney—kidney cancer	0.000794	0.0244	CbGeAlD
Celecoxib—CA5B—gonad—kidney cancer	0.000661	0.0203	CbGeAlD
Celecoxib—CA5B—cardiac atrium—kidney cancer	0.00066	0.0203	CbGeAlD
Celecoxib—ABCC4—nephron tubule—kidney cancer	0.000609	0.0187	CbGeAlD
Celecoxib—CA4—nephron tubule—kidney cancer	0.00056	0.0172	CbGeAlD
Celecoxib—ABCC4—renal system—kidney cancer	0.000553	0.017	CbGeAlD
Celecoxib—ABCC4—kidney—kidney cancer	0.000535	0.0164	CbGeAlD
Celecoxib—ABCC4—cortex of kidney—kidney cancer	0.000521	0.016	CbGeAlD
Celecoxib—CA4—renal system—kidney cancer	0.000509	0.0156	CbGeAlD
Celecoxib—CA4—kidney—kidney cancer	0.000492	0.0151	CbGeAlD
Celecoxib—CA4—cortex of kidney—kidney cancer	0.000479	0.0147	CbGeAlD
Celecoxib—CA2—nephron tubule—kidney cancer	0.000464	0.0142	CbGeAlD
Celecoxib—CA4—cardiac atrium—kidney cancer	0.000456	0.014	CbGeAlD
Celecoxib—CA2—renal system—kidney cancer	0.000422	0.0129	CbGeAlD
Celecoxib—CA2—kidney—kidney cancer	0.000408	0.0125	CbGeAlD
Celecoxib—CA2—cortex of kidney—kidney cancer	0.000397	0.0122	CbGeAlD
Celecoxib—CA2—cardiac atrium—kidney cancer	0.000378	0.0116	CbGeAlD
Celecoxib—PTGS2—renal system—kidney cancer	0.000311	0.00956	CbGeAlD
Celecoxib—PTGS2—kidney—kidney cancer	0.000301	0.00924	CbGeAlD
Celecoxib—CYP3A4—renal system—kidney cancer	0.000272	0.00835	CbGeAlD
Celecoxib—CYP2D6—renal system—kidney cancer	0.000268	0.00822	CbGeAlD
Celecoxib—CYP3A4—kidney—kidney cancer	0.000263	0.00808	CbGeAlD
Celecoxib—CYP2D6—kidney—kidney cancer	0.000259	0.00795	CbGeAlD
Celecoxib—Etoricoxib—PTGS2—kidney cancer	0.000239	1	CrCbGaD
Celecoxib—Gastrointestinal pain—Vincristine—kidney cancer	3.89e-05	0.000229	CcSEcCtD
Celecoxib—Dizziness—Sorafenib—kidney cancer	3.86e-05	0.000227	CcSEcCtD
Celecoxib—Constipation—Gemcitabine—kidney cancer	3.86e-05	0.000227	CcSEcCtD
Celecoxib—Nausea—Erlotinib—kidney cancer	3.86e-05	0.000227	CcSEcCtD
Celecoxib—Alopecia—Capecitabine—kidney cancer	3.85e-05	0.000227	CcSEcCtD
Celecoxib—Dry mouth—Paclitaxel—kidney cancer	3.85e-05	0.000227	CcSEcCtD
Celecoxib—Diarrhoea—Sunitinib—kidney cancer	3.84e-05	0.000226	CcSEcCtD
Celecoxib—Ataxia—Doxorubicin—kidney cancer	3.82e-05	0.000225	CcSEcCtD
Celecoxib—Mental disorder—Capecitabine—kidney cancer	3.82e-05	0.000225	CcSEcCtD
Celecoxib—Asthenia—Dactinomycin—kidney cancer	3.82e-05	0.000225	CcSEcCtD
Celecoxib—Confusional state—Paclitaxel—kidney cancer	3.81e-05	0.000224	CcSEcCtD
Celecoxib—Blood creatinine increased—Doxorubicin—kidney cancer	3.81e-05	0.000224	CcSEcCtD
Celecoxib—Anaphylactic shock—Paclitaxel—kidney cancer	3.77e-05	0.000222	CcSEcCtD
Celecoxib—Oedema—Paclitaxel—kidney cancer	3.77e-05	0.000222	CcSEcCtD
Celecoxib—Body temperature increased—Vincristine—kidney cancer	3.76e-05	0.000221	CcSEcCtD
Celecoxib—Abdominal pain—Vincristine—kidney cancer	3.76e-05	0.000221	CcSEcCtD
Celecoxib—Liver function test abnormal—Doxorubicin—kidney cancer	3.75e-05	0.000221	CcSEcCtD
Celecoxib—Infection—Paclitaxel—kidney cancer	3.75e-05	0.000221	CcSEcCtD
Celecoxib—Flatulence—Capecitabine—kidney cancer	3.74e-05	0.00022	CcSEcCtD
Celecoxib—Dry skin—Doxorubicin—kidney cancer	3.72e-05	0.000219	CcSEcCtD
Celecoxib—Dysgeusia—Capecitabine—kidney cancer	3.72e-05	0.000219	CcSEcCtD
Celecoxib—Dizziness—Sunitinib—kidney cancer	3.72e-05	0.000219	CcSEcCtD
Celecoxib—Feeling abnormal—Gemcitabine—kidney cancer	3.72e-05	0.000219	CcSEcCtD
Celecoxib—Shock—Paclitaxel—kidney cancer	3.71e-05	0.000219	CcSEcCtD
Celecoxib—Vomiting—Sorafenib—kidney cancer	3.71e-05	0.000218	CcSEcCtD
Celecoxib—Abdominal pain upper—Doxorubicin—kidney cancer	3.71e-05	0.000218	CcSEcCtD
Celecoxib—Nervous system disorder—Paclitaxel—kidney cancer	3.7e-05	0.000218	CcSEcCtD
Celecoxib—Hypokalaemia—Doxorubicin—kidney cancer	3.7e-05	0.000218	CcSEcCtD
Celecoxib—Thrombocytopenia—Paclitaxel—kidney cancer	3.7e-05	0.000217	CcSEcCtD
Celecoxib—Tachycardia—Paclitaxel—kidney cancer	3.68e-05	0.000217	CcSEcCtD
Celecoxib—Rash—Sorafenib—kidney cancer	3.68e-05	0.000217	CcSEcCtD
Celecoxib—Dermatitis—Sorafenib—kidney cancer	3.68e-05	0.000216	CcSEcCtD
Celecoxib—Back pain—Capecitabine—kidney cancer	3.67e-05	0.000216	CcSEcCtD
Celecoxib—Breast disorder—Doxorubicin—kidney cancer	3.67e-05	0.000216	CcSEcCtD
Celecoxib—Skin disorder—Paclitaxel—kidney cancer	3.67e-05	0.000216	CcSEcCtD
Celecoxib—Aspartate aminotransferase increased—Doxorubicin—kidney cancer	3.66e-05	0.000215	CcSEcCtD
Celecoxib—Toxic epidermal necrolysis—Doxorubicin—kidney cancer	3.66e-05	0.000215	CcSEcCtD
Celecoxib—Headache—Sorafenib—kidney cancer	3.66e-05	0.000215	CcSEcCtD
Celecoxib—Muscle spasms—Capecitabine—kidney cancer	3.65e-05	0.000215	CcSEcCtD
Celecoxib—Hyperhidrosis—Paclitaxel—kidney cancer	3.65e-05	0.000215	CcSEcCtD
Celecoxib—Diarrhoea—Dactinomycin—kidney cancer	3.64e-05	0.000214	CcSEcCtD
Celecoxib—Nasopharyngitis—Doxorubicin—kidney cancer	3.63e-05	0.000214	CcSEcCtD
Celecoxib—Anorexia—Paclitaxel—kidney cancer	3.6e-05	0.000212	CcSEcCtD
Celecoxib—Gastritis—Doxorubicin—kidney cancer	3.6e-05	0.000212	CcSEcCtD
Celecoxib—Alanine aminotransferase increased—Doxorubicin—kidney cancer	3.58e-05	0.000211	CcSEcCtD
Celecoxib—Vision blurred—Capecitabine—kidney cancer	3.58e-05	0.00021	CcSEcCtD
Celecoxib—Vomiting—Sunitinib—kidney cancer	3.57e-05	0.00021	CcSEcCtD
Celecoxib—Body temperature increased—Gemcitabine—kidney cancer	3.56e-05	0.00021	CcSEcCtD
Celecoxib—Rash—Sunitinib—kidney cancer	3.54e-05	0.000208	CcSEcCtD
Celecoxib—Dermatitis—Sunitinib—kidney cancer	3.54e-05	0.000208	CcSEcCtD
Celecoxib—Headache—Sunitinib—kidney cancer	3.52e-05	0.000207	CcSEcCtD
Celecoxib—Dysphagia—Doxorubicin—kidney cancer	3.51e-05	0.000207	CcSEcCtD
Celecoxib—Anaemia—Capecitabine—kidney cancer	3.51e-05	0.000206	CcSEcCtD
Celecoxib—Hypersensitivity—Vincristine—kidney cancer	3.5e-05	0.000206	CcSEcCtD
Celecoxib—Eosinophilia—Doxorubicin—kidney cancer	3.48e-05	0.000205	CcSEcCtD
Celecoxib—Nausea—Sorafenib—kidney cancer	3.47e-05	0.000204	CcSEcCtD
Celecoxib—Pancreatitis—Doxorubicin—kidney cancer	3.44e-05	0.000203	CcSEcCtD
Celecoxib—Musculoskeletal discomfort—Paclitaxel—kidney cancer	3.44e-05	0.000202	CcSEcCtD
Celecoxib—Angina pectoris—Doxorubicin—kidney cancer	3.42e-05	0.000201	CcSEcCtD
Celecoxib—Insomnia—Paclitaxel—kidney cancer	3.41e-05	0.000201	CcSEcCtD
Celecoxib—Vertigo—Capecitabine—kidney cancer	3.41e-05	0.000201	CcSEcCtD
Celecoxib—Asthenia—Vincristine—kidney cancer	3.41e-05	0.000201	CcSEcCtD
Celecoxib—Syncope—Capecitabine—kidney cancer	3.4e-05	0.0002	CcSEcCtD
Celecoxib—Leukopenia—Capecitabine—kidney cancer	3.4e-05	0.0002	CcSEcCtD
Celecoxib—Paraesthesia—Paclitaxel—kidney cancer	3.39e-05	0.000199	CcSEcCtD
Celecoxib—Vomiting—Dactinomycin—kidney cancer	3.38e-05	0.000199	CcSEcCtD
Celecoxib—Bronchitis—Doxorubicin—kidney cancer	3.38e-05	0.000199	CcSEcCtD
Celecoxib—Dyspnoea—Paclitaxel—kidney cancer	3.37e-05	0.000198	CcSEcCtD
Celecoxib—Somnolence—Paclitaxel—kidney cancer	3.36e-05	0.000197	CcSEcCtD
Celecoxib—Palpitations—Capecitabine—kidney cancer	3.35e-05	0.000197	CcSEcCtD
Celecoxib—Rash—Dactinomycin—kidney cancer	3.35e-05	0.000197	CcSEcCtD
Celecoxib—Nausea—Sunitinib—kidney cancer	3.34e-05	0.000196	CcSEcCtD
Celecoxib—Loss of consciousness—Capecitabine—kidney cancer	3.34e-05	0.000196	CcSEcCtD
Celecoxib—Pancytopenia—Doxorubicin—kidney cancer	3.33e-05	0.000196	CcSEcCtD
Celecoxib—Dyspepsia—Paclitaxel—kidney cancer	3.32e-05	0.000196	CcSEcCtD
Celecoxib—Cough—Capecitabine—kidney cancer	3.31e-05	0.000195	CcSEcCtD
Celecoxib—Dysuria—Doxorubicin—kidney cancer	3.28e-05	0.000193	CcSEcCtD
Celecoxib—Decreased appetite—Paclitaxel—kidney cancer	3.28e-05	0.000193	CcSEcCtD
Celecoxib—Hypertension—Capecitabine—kidney cancer	3.28e-05	0.000193	CcSEcCtD
Celecoxib—Upper respiratory tract infection—Doxorubicin—kidney cancer	3.26e-05	0.000192	CcSEcCtD
Celecoxib—Gastrointestinal disorder—Paclitaxel—kidney cancer	3.26e-05	0.000192	CcSEcCtD
Celecoxib—Fatigue—Paclitaxel—kidney cancer	3.25e-05	0.000191	CcSEcCtD
Celecoxib—Diarrhoea—Vincristine—kidney cancer	3.25e-05	0.000191	CcSEcCtD
Celecoxib—Pollakiuria—Doxorubicin—kidney cancer	3.24e-05	0.000191	CcSEcCtD
Celecoxib—Asthenia—Gemcitabine—kidney cancer	3.23e-05	0.00019	CcSEcCtD
Celecoxib—Chest pain—Capecitabine—kidney cancer	3.23e-05	0.00019	CcSEcCtD
Celecoxib—Arthralgia—Capecitabine—kidney cancer	3.23e-05	0.00019	CcSEcCtD
Celecoxib—Myalgia—Capecitabine—kidney cancer	3.23e-05	0.00019	CcSEcCtD
Celecoxib—Constipation—Paclitaxel—kidney cancer	3.23e-05	0.00019	CcSEcCtD
Celecoxib—Anxiety—Capecitabine—kidney cancer	3.22e-05	0.000189	CcSEcCtD
Celecoxib—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—kidney cancer	3.21e-05	0.000189	CcSEcCtD
Celecoxib—Photosensitivity reaction—Doxorubicin—kidney cancer	3.2e-05	0.000189	CcSEcCtD
Celecoxib—Weight increased—Doxorubicin—kidney cancer	3.2e-05	0.000188	CcSEcCtD
Celecoxib—Pruritus—Gemcitabine—kidney cancer	3.19e-05	0.000188	CcSEcCtD
Celecoxib—Hyperglycaemia—Doxorubicin—kidney cancer	3.17e-05	0.000186	CcSEcCtD
Celecoxib—Dry mouth—Capecitabine—kidney cancer	3.16e-05	0.000186	CcSEcCtD
Celecoxib—Nausea—Dactinomycin—kidney cancer	3.16e-05	0.000186	CcSEcCtD
Celecoxib—Pneumonia—Doxorubicin—kidney cancer	3.15e-05	0.000185	CcSEcCtD
Celecoxib—Dizziness—Vincristine—kidney cancer	3.14e-05	0.000185	CcSEcCtD
Celecoxib—Infestation NOS—Doxorubicin—kidney cancer	3.13e-05	0.000184	CcSEcCtD
Celecoxib—Infestation—Doxorubicin—kidney cancer	3.13e-05	0.000184	CcSEcCtD
Celecoxib—Confusional state—Capecitabine—kidney cancer	3.12e-05	0.000184	CcSEcCtD
Celecoxib—Feeling abnormal—Paclitaxel—kidney cancer	3.11e-05	0.000183	CcSEcCtD
Celecoxib—Stevens-Johnson syndrome—Doxorubicin—kidney cancer	3.1e-05	0.000183	CcSEcCtD
Celecoxib—Oedema—Capecitabine—kidney cancer	3.1e-05	0.000182	CcSEcCtD
Celecoxib—Gastrointestinal pain—Paclitaxel—kidney cancer	3.09e-05	0.000182	CcSEcCtD
Celecoxib—Diarrhoea—Gemcitabine—kidney cancer	3.08e-05	0.000182	CcSEcCtD
Celecoxib—Infection—Capecitabine—kidney cancer	3.08e-05	0.000181	CcSEcCtD
Celecoxib—Neuropathy peripheral—Doxorubicin—kidney cancer	3.07e-05	0.000181	CcSEcCtD
Celecoxib—Stomatitis—Doxorubicin—kidney cancer	3.05e-05	0.00018	CcSEcCtD
Celecoxib—Jaundice—Doxorubicin—kidney cancer	3.05e-05	0.00018	CcSEcCtD
Celecoxib—Shock—Capecitabine—kidney cancer	3.05e-05	0.000179	CcSEcCtD
Celecoxib—Conjunctivitis—Doxorubicin—kidney cancer	3.04e-05	0.000179	CcSEcCtD
Celecoxib—Urinary tract infection—Doxorubicin—kidney cancer	3.04e-05	0.000179	CcSEcCtD
Celecoxib—Nervous system disorder—Capecitabine—kidney cancer	3.04e-05	0.000179	CcSEcCtD
Celecoxib—Thrombocytopenia—Capecitabine—kidney cancer	3.03e-05	0.000178	CcSEcCtD
Celecoxib—Tachycardia—Capecitabine—kidney cancer	3.02e-05	0.000178	CcSEcCtD
Celecoxib—Vomiting—Vincristine—kidney cancer	3.02e-05	0.000178	CcSEcCtD
Celecoxib—Skin disorder—Capecitabine—kidney cancer	3.01e-05	0.000177	CcSEcCtD
Celecoxib—Urticaria—Paclitaxel—kidney cancer	3e-05	0.000176	CcSEcCtD
Celecoxib—Rash—Vincristine—kidney cancer	3e-05	0.000176	CcSEcCtD
Celecoxib—Hyperhidrosis—Capecitabine—kidney cancer	2.99e-05	0.000176	CcSEcCtD
Celecoxib—Dermatitis—Vincristine—kidney cancer	2.99e-05	0.000176	CcSEcCtD
Celecoxib—Haematuria—Doxorubicin—kidney cancer	2.98e-05	0.000176	CcSEcCtD
Celecoxib—Abdominal pain—Paclitaxel—kidney cancer	2.98e-05	0.000176	CcSEcCtD
Celecoxib—Body temperature increased—Paclitaxel—kidney cancer	2.98e-05	0.000176	CcSEcCtD
Celecoxib—Headache—Vincristine—kidney cancer	2.98e-05	0.000175	CcSEcCtD
Celecoxib—Hepatobiliary disease—Doxorubicin—kidney cancer	2.96e-05	0.000174	CcSEcCtD
Celecoxib—Epistaxis—Doxorubicin—kidney cancer	2.95e-05	0.000174	CcSEcCtD
Celecoxib—Anorexia—Capecitabine—kidney cancer	2.95e-05	0.000174	CcSEcCtD
Celecoxib—Sinusitis—Doxorubicin—kidney cancer	2.94e-05	0.000173	CcSEcCtD
Celecoxib—Agranulocytosis—Doxorubicin—kidney cancer	2.92e-05	0.000172	CcSEcCtD
Celecoxib—Vomiting—Gemcitabine—kidney cancer	2.87e-05	0.000169	CcSEcCtD
Celecoxib—Rash—Gemcitabine—kidney cancer	2.84e-05	0.000167	CcSEcCtD
Celecoxib—Dermatitis—Gemcitabine—kidney cancer	2.84e-05	0.000167	CcSEcCtD
Celecoxib—Haemoglobin—Doxorubicin—kidney cancer	2.82e-05	0.000166	CcSEcCtD
Celecoxib—Headache—Gemcitabine—kidney cancer	2.82e-05	0.000166	CcSEcCtD
Celecoxib—Nausea—Vincristine—kidney cancer	2.82e-05	0.000166	CcSEcCtD
Celecoxib—Musculoskeletal discomfort—Capecitabine—kidney cancer	2.82e-05	0.000166	CcSEcCtD
Celecoxib—Rhinitis—Doxorubicin—kidney cancer	2.82e-05	0.000166	CcSEcCtD
Celecoxib—Hepatitis—Doxorubicin—kidney cancer	2.81e-05	0.000165	CcSEcCtD
Celecoxib—Haemorrhage—Doxorubicin—kidney cancer	2.81e-05	0.000165	CcSEcCtD
Celecoxib—Insomnia—Capecitabine—kidney cancer	2.8e-05	0.000165	CcSEcCtD
Celecoxib—Hypoaesthesia—Doxorubicin—kidney cancer	2.8e-05	0.000165	CcSEcCtD
Celecoxib—Pharyngitis—Doxorubicin—kidney cancer	2.79e-05	0.000164	CcSEcCtD
Celecoxib—Paraesthesia—Capecitabine—kidney cancer	2.78e-05	0.000164	CcSEcCtD
Celecoxib—Hypersensitivity—Paclitaxel—kidney cancer	2.78e-05	0.000164	CcSEcCtD
Celecoxib—Urinary tract disorder—Doxorubicin—kidney cancer	2.78e-05	0.000163	CcSEcCtD
Celecoxib—Oedema peripheral—Doxorubicin—kidney cancer	2.77e-05	0.000163	CcSEcCtD
Celecoxib—Connective tissue disorder—Doxorubicin—kidney cancer	2.76e-05	0.000163	CcSEcCtD
Celecoxib—Dyspnoea—Capecitabine—kidney cancer	2.76e-05	0.000163	CcSEcCtD
Celecoxib—Urethral disorder—Doxorubicin—kidney cancer	2.75e-05	0.000162	CcSEcCtD
Celecoxib—Dyspepsia—Capecitabine—kidney cancer	2.73e-05	0.00016	CcSEcCtD
Celecoxib—Asthenia—Paclitaxel—kidney cancer	2.71e-05	0.000159	CcSEcCtD
Celecoxib—Decreased appetite—Capecitabine—kidney cancer	2.69e-05	0.000158	CcSEcCtD
Celecoxib—Nausea—Gemcitabine—kidney cancer	2.68e-05	0.000158	CcSEcCtD
Celecoxib—Gastrointestinal disorder—Capecitabine—kidney cancer	2.67e-05	0.000157	CcSEcCtD
Celecoxib—Fatigue—Capecitabine—kidney cancer	2.67e-05	0.000157	CcSEcCtD
Celecoxib—Pruritus—Paclitaxel—kidney cancer	2.67e-05	0.000157	CcSEcCtD
Celecoxib—Erythema multiforme—Doxorubicin—kidney cancer	2.66e-05	0.000156	CcSEcCtD
Celecoxib—Constipation—Capecitabine—kidney cancer	2.65e-05	0.000156	CcSEcCtD
Celecoxib—Eye disorder—Doxorubicin—kidney cancer	2.63e-05	0.000155	CcSEcCtD
Celecoxib—Tinnitus—Doxorubicin—kidney cancer	2.62e-05	0.000154	CcSEcCtD
Celecoxib—Flushing—Doxorubicin—kidney cancer	2.61e-05	0.000153	CcSEcCtD
Celecoxib—Cardiac disorder—Doxorubicin—kidney cancer	2.61e-05	0.000153	CcSEcCtD
Celecoxib—Diarrhoea—Paclitaxel—kidney cancer	2.58e-05	0.000152	CcSEcCtD
Celecoxib—Feeling abnormal—Capecitabine—kidney cancer	2.55e-05	0.00015	CcSEcCtD
Celecoxib—Angiopathy—Doxorubicin—kidney cancer	2.55e-05	0.00015	CcSEcCtD
Celecoxib—Immune system disorder—Doxorubicin—kidney cancer	2.54e-05	0.000149	CcSEcCtD
Celecoxib—Gastrointestinal pain—Capecitabine—kidney cancer	2.53e-05	0.000149	CcSEcCtD
Celecoxib—Mediastinal disorder—Doxorubicin—kidney cancer	2.53e-05	0.000149	CcSEcCtD
Celecoxib—Arrhythmia—Doxorubicin—kidney cancer	2.51e-05	0.000148	CcSEcCtD
Celecoxib—Dizziness—Paclitaxel—kidney cancer	2.5e-05	0.000147	CcSEcCtD
Celecoxib—Alopecia—Doxorubicin—kidney cancer	2.48e-05	0.000146	CcSEcCtD
Celecoxib—Mental disorder—Doxorubicin—kidney cancer	2.46e-05	0.000145	CcSEcCtD
Celecoxib—Urticaria—Capecitabine—kidney cancer	2.46e-05	0.000145	CcSEcCtD
Celecoxib—Abdominal pain—Capecitabine—kidney cancer	2.45e-05	0.000144	CcSEcCtD
Celecoxib—Body temperature increased—Capecitabine—kidney cancer	2.45e-05	0.000144	CcSEcCtD
Celecoxib—Flatulence—Doxorubicin—kidney cancer	2.41e-05	0.000142	CcSEcCtD
Celecoxib—Tension—Doxorubicin—kidney cancer	2.4e-05	0.000141	CcSEcCtD
Celecoxib—Vomiting—Paclitaxel—kidney cancer	2.4e-05	0.000141	CcSEcCtD
Celecoxib—Dysgeusia—Doxorubicin—kidney cancer	2.4e-05	0.000141	CcSEcCtD
Celecoxib—Rash—Paclitaxel—kidney cancer	2.38e-05	0.00014	CcSEcCtD
Celecoxib—Dermatitis—Paclitaxel—kidney cancer	2.38e-05	0.00014	CcSEcCtD
Celecoxib—Nervousness—Doxorubicin—kidney cancer	2.38e-05	0.00014	CcSEcCtD
Celecoxib—Back pain—Doxorubicin—kidney cancer	2.37e-05	0.000139	CcSEcCtD
Celecoxib—Headache—Paclitaxel—kidney cancer	2.36e-05	0.000139	CcSEcCtD
Celecoxib—Muscle spasms—Doxorubicin—kidney cancer	2.35e-05	0.000138	CcSEcCtD
Celecoxib—Vision blurred—Doxorubicin—kidney cancer	2.31e-05	0.000136	CcSEcCtD
Celecoxib—Hypersensitivity—Capecitabine—kidney cancer	2.28e-05	0.000134	CcSEcCtD
Celecoxib—Anaemia—Doxorubicin—kidney cancer	2.26e-05	0.000133	CcSEcCtD
Celecoxib—Nausea—Paclitaxel—kidney cancer	2.24e-05	0.000132	CcSEcCtD
Celecoxib—Asthenia—Capecitabine—kidney cancer	2.22e-05	0.000131	CcSEcCtD
Celecoxib—Vertigo—Doxorubicin—kidney cancer	2.2e-05	0.000129	CcSEcCtD
Celecoxib—Syncope—Doxorubicin—kidney cancer	2.19e-05	0.000129	CcSEcCtD
Celecoxib—Pruritus—Capecitabine—kidney cancer	2.19e-05	0.000129	CcSEcCtD
Celecoxib—Leukopenia—Doxorubicin—kidney cancer	2.19e-05	0.000129	CcSEcCtD
Celecoxib—Palpitations—Doxorubicin—kidney cancer	2.16e-05	0.000127	CcSEcCtD
Celecoxib—Loss of consciousness—Doxorubicin—kidney cancer	2.15e-05	0.000127	CcSEcCtD
Celecoxib—Cough—Doxorubicin—kidney cancer	2.13e-05	0.000126	CcSEcCtD
Celecoxib—Diarrhoea—Capecitabine—kidney cancer	2.12e-05	0.000125	CcSEcCtD
Celecoxib—Hypertension—Doxorubicin—kidney cancer	2.11e-05	0.000124	CcSEcCtD
Celecoxib—Chest pain—Doxorubicin—kidney cancer	2.08e-05	0.000123	CcSEcCtD
Celecoxib—Arthralgia—Doxorubicin—kidney cancer	2.08e-05	0.000123	CcSEcCtD
Celecoxib—Myalgia—Doxorubicin—kidney cancer	2.08e-05	0.000123	CcSEcCtD
Celecoxib—Anxiety—Doxorubicin—kidney cancer	2.08e-05	0.000122	CcSEcCtD
Celecoxib—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—kidney cancer	2.07e-05	0.000122	CcSEcCtD
Celecoxib—Dizziness—Capecitabine—kidney cancer	2.05e-05	0.000121	CcSEcCtD
Celecoxib—Dry mouth—Doxorubicin—kidney cancer	2.04e-05	0.00012	CcSEcCtD
Celecoxib—Confusional state—Doxorubicin—kidney cancer	2.01e-05	0.000118	CcSEcCtD
Celecoxib—Anaphylactic shock—Doxorubicin—kidney cancer	2e-05	0.000117	CcSEcCtD
Celecoxib—Oedema—Doxorubicin—kidney cancer	2e-05	0.000117	CcSEcCtD
Celecoxib—Infection—Doxorubicin—kidney cancer	1.98e-05	0.000117	CcSEcCtD
Celecoxib—Vomiting—Capecitabine—kidney cancer	1.97e-05	0.000116	CcSEcCtD
Celecoxib—Shock—Doxorubicin—kidney cancer	1.96e-05	0.000116	CcSEcCtD
Celecoxib—Nervous system disorder—Doxorubicin—kidney cancer	1.96e-05	0.000115	CcSEcCtD
Celecoxib—Thrombocytopenia—Doxorubicin—kidney cancer	1.95e-05	0.000115	CcSEcCtD
Celecoxib—Rash—Capecitabine—kidney cancer	1.95e-05	0.000115	CcSEcCtD
Celecoxib—Dermatitis—Capecitabine—kidney cancer	1.95e-05	0.000115	CcSEcCtD
Celecoxib—Tachycardia—Doxorubicin—kidney cancer	1.95e-05	0.000115	CcSEcCtD
Celecoxib—Headache—Capecitabine—kidney cancer	1.94e-05	0.000114	CcSEcCtD
Celecoxib—Skin disorder—Doxorubicin—kidney cancer	1.94e-05	0.000114	CcSEcCtD
Celecoxib—Hyperhidrosis—Doxorubicin—kidney cancer	1.93e-05	0.000114	CcSEcCtD
Celecoxib—Anorexia—Doxorubicin—kidney cancer	1.9e-05	0.000112	CcSEcCtD
Celecoxib—Nausea—Capecitabine—kidney cancer	1.84e-05	0.000108	CcSEcCtD
Celecoxib—Musculoskeletal discomfort—Doxorubicin—kidney cancer	1.82e-05	0.000107	CcSEcCtD
Celecoxib—Insomnia—Doxorubicin—kidney cancer	1.81e-05	0.000106	CcSEcCtD
Celecoxib—Paraesthesia—Doxorubicin—kidney cancer	1.79e-05	0.000106	CcSEcCtD
Celecoxib—Dyspnoea—Doxorubicin—kidney cancer	1.78e-05	0.000105	CcSEcCtD
Celecoxib—Somnolence—Doxorubicin—kidney cancer	1.78e-05	0.000104	CcSEcCtD
Celecoxib—Dyspepsia—Doxorubicin—kidney cancer	1.76e-05	0.000103	CcSEcCtD
Celecoxib—Decreased appetite—Doxorubicin—kidney cancer	1.74e-05	0.000102	CcSEcCtD
Celecoxib—Gastrointestinal disorder—Doxorubicin—kidney cancer	1.72e-05	0.000101	CcSEcCtD
Celecoxib—Fatigue—Doxorubicin—kidney cancer	1.72e-05	0.000101	CcSEcCtD
Celecoxib—Constipation—Doxorubicin—kidney cancer	1.71e-05	0.0001	CcSEcCtD
Celecoxib—Feeling abnormal—Doxorubicin—kidney cancer	1.65e-05	9.68e-05	CcSEcCtD
Celecoxib—Gastrointestinal pain—Doxorubicin—kidney cancer	1.63e-05	9.61e-05	CcSEcCtD
Celecoxib—Urticaria—Doxorubicin—kidney cancer	1.59e-05	9.33e-05	CcSEcCtD
Celecoxib—Abdominal pain—Doxorubicin—kidney cancer	1.58e-05	9.29e-05	CcSEcCtD
Celecoxib—Body temperature increased—Doxorubicin—kidney cancer	1.58e-05	9.29e-05	CcSEcCtD
Celecoxib—Hypersensitivity—Doxorubicin—kidney cancer	1.47e-05	8.66e-05	CcSEcCtD
Celecoxib—Asthenia—Doxorubicin—kidney cancer	1.43e-05	8.43e-05	CcSEcCtD
Celecoxib—Pruritus—Doxorubicin—kidney cancer	1.41e-05	8.31e-05	CcSEcCtD
Celecoxib—Diarrhoea—Doxorubicin—kidney cancer	1.37e-05	8.04e-05	CcSEcCtD
Celecoxib—Dizziness—Doxorubicin—kidney cancer	1.32e-05	7.77e-05	CcSEcCtD
Celecoxib—Vomiting—Doxorubicin—kidney cancer	1.27e-05	7.47e-05	CcSEcCtD
Celecoxib—Rash—Doxorubicin—kidney cancer	1.26e-05	7.41e-05	CcSEcCtD
Celecoxib—Dermatitis—Doxorubicin—kidney cancer	1.26e-05	7.4e-05	CcSEcCtD
Celecoxib—Headache—Doxorubicin—kidney cancer	1.25e-05	7.36e-05	CcSEcCtD
Celecoxib—Nausea—Doxorubicin—kidney cancer	1.19e-05	6.98e-05	CcSEcCtD
Celecoxib—MAPK14—Signaling Pathways—JUNB—kidney cancer	4.93e-06	4.2e-05	CbGpPWpGaD
Celecoxib—CYP2D6—Metabolism—LDHB—kidney cancer	4.88e-06	4.15e-05	CbGpPWpGaD
Celecoxib—ABCC4—Hemostasis—KRAS—kidney cancer	4.84e-06	4.12e-05	CbGpPWpGaD
Celecoxib—CYP2C9—Metabolism—LDHB—kidney cancer	4.84e-06	4.12e-05	CbGpPWpGaD
Celecoxib—CA14—Metabolism—PIK3CA—kidney cancer	4.82e-06	4.1e-05	CbGpPWpGaD
Celecoxib—MAPK14—Developmental Biology—MAPK3—kidney cancer	4.81e-06	4.09e-05	CbGpPWpGaD
Celecoxib—PDPK1—Immune System—MAPK3—kidney cancer	4.76e-06	4.05e-05	CbGpPWpGaD
Celecoxib—PDPK1—GPCR downstream signaling—PIK3CA—kidney cancer	4.74e-06	4.03e-05	CbGpPWpGaD
Celecoxib—ALB—Platelet activation, signaling and aggregation—MAPK3—kidney cancer	4.73e-06	4.03e-05	CbGpPWpGaD
Celecoxib—MAPK14—Hemostasis—MAPK3—kidney cancer	4.72e-06	4.02e-05	CbGpPWpGaD
Celecoxib—CA5A—Metabolism—PIK3CA—kidney cancer	4.69e-06	4e-05	CbGpPWpGaD
Celecoxib—CA6—Metabolism—PIK3CA—kidney cancer	4.69e-06	4e-05	CbGpPWpGaD
Celecoxib—PDPK1—Signaling by GPCR—KRAS—kidney cancer	4.68e-06	3.99e-05	CbGpPWpGaD
Celecoxib—PTGS2—Metabolism of lipids and lipoproteins—POMC—kidney cancer	4.61e-06	3.93e-05	CbGpPWpGaD
Celecoxib—CA4—Metabolism—PTEN—kidney cancer	4.59e-06	3.91e-05	CbGpPWpGaD
Celecoxib—MAPK14—Developmental Biology—MAPK1—kidney cancer	4.57e-06	3.9e-05	CbGpPWpGaD
Celecoxib—PTGS2—Metabolism—GSTT1—kidney cancer	4.56e-06	3.89e-05	CbGpPWpGaD
Celecoxib—PTGS2—Metabolism—ACHE—kidney cancer	4.56e-06	3.89e-05	CbGpPWpGaD
Celecoxib—PTGS2—Disease—SLC2A1—kidney cancer	4.53e-06	3.86e-05	CbGpPWpGaD
Celecoxib—PDPK1—Immune System—MAPK1—kidney cancer	4.53e-06	3.86e-05	CbGpPWpGaD
Celecoxib—ALB—Platelet activation, signaling and aggregation—MAPK1—kidney cancer	4.5e-06	3.83e-05	CbGpPWpGaD
Celecoxib—PTGS2—Disease—JUNB—kidney cancer	4.5e-06	3.83e-05	CbGpPWpGaD
Celecoxib—MAPK14—Hemostasis—MAPK1—kidney cancer	4.49e-06	3.82e-05	CbGpPWpGaD
Celecoxib—ABCC4—Hemostasis—PIK3CA—kidney cancer	4.45e-06	3.79e-05	CbGpPWpGaD
Celecoxib—CA2—Metabolism—PTEN—kidney cancer	4.4e-06	3.75e-05	CbGpPWpGaD
Celecoxib—PDPK1—Disease—MAPK3—kidney cancer	4.39e-06	3.74e-05	CbGpPWpGaD
Celecoxib—CA5B—Metabolism—PIK3CA—kidney cancer	4.38e-06	3.73e-05	CbGpPWpGaD
Celecoxib—MAPK14—Immune System—KIT—kidney cancer	4.37e-06	3.72e-05	CbGpPWpGaD
Celecoxib—ALB—Metabolism—CRABP1—kidney cancer	4.36e-06	3.71e-05	CbGpPWpGaD
Celecoxib—PTGS2—Metabolism—SCARB1—kidney cancer	4.32e-06	3.68e-05	CbGpPWpGaD
Celecoxib—MAPK14—Developmental Biology—KRAS—kidney cancer	4.32e-06	3.68e-05	CbGpPWpGaD
Celecoxib—ABCC4—Hemostasis—TP53—kidney cancer	4.3e-06	3.66e-05	CbGpPWpGaD
Celecoxib—PDPK1—Signaling by GPCR—PIK3CA—kidney cancer	4.3e-06	3.66e-05	CbGpPWpGaD
Celecoxib—CYP3A4—Metabolism—PPAT—kidney cancer	4.29e-06	3.65e-05	CbGpPWpGaD
Celecoxib—CYP3A4—Metabolism—GLIPR1—kidney cancer	4.29e-06	3.65e-05	CbGpPWpGaD
Celecoxib—PTGS2—Metabolism—PTGS1—kidney cancer	4.28e-06	3.64e-05	CbGpPWpGaD
Celecoxib—PDPK1—Immune System—KRAS—kidney cancer	4.28e-06	3.64e-05	CbGpPWpGaD
Celecoxib—PDPK1—Disease—MYC—kidney cancer	4.27e-06	3.64e-05	CbGpPWpGaD
Celecoxib—PDPK1—Signaling Pathways—RAF1—kidney cancer	4.27e-06	3.63e-05	CbGpPWpGaD
Celecoxib—CA9—Metabolism—PTGS2—kidney cancer	4.25e-06	3.62e-05	CbGpPWpGaD
Celecoxib—PDPK1—Signaling Pathways—RELA—kidney cancer	4.25e-06	3.62e-05	CbGpPWpGaD
Celecoxib—MAPK14—Innate Immune System—MAPK3—kidney cancer	4.25e-06	3.62e-05	CbGpPWpGaD
Celecoxib—MAPK14—Hemostasis—KRAS—kidney cancer	4.24e-06	3.61e-05	CbGpPWpGaD
Celecoxib—CYP2D6—Metabolism—CA9—kidney cancer	4.23e-06	3.6e-05	CbGpPWpGaD
Celecoxib—PDPK1—Signaling Pathways—ERBB2—kidney cancer	4.22e-06	3.6e-05	CbGpPWpGaD
Celecoxib—PTGS2—Metabolism—PSMD7—kidney cancer	4.19e-06	3.57e-05	CbGpPWpGaD
Celecoxib—CYP2C9—Metabolism—CA9—kidney cancer	4.19e-06	3.57e-05	CbGpPWpGaD
Celecoxib—PDPK1—Disease—MAPK1—kidney cancer	4.18e-06	3.56e-05	CbGpPWpGaD
Celecoxib—PDPK1—Signaling Pathways—MTOR—kidney cancer	4.17e-06	3.55e-05	CbGpPWpGaD
Celecoxib—CYP2C9—Metabolism of lipids and lipoproteins—CYP1A1—kidney cancer	4.1e-06	3.49e-05	CbGpPWpGaD
Celecoxib—CA12—Metabolism—PIK3CA—kidney cancer	4.06e-06	3.46e-05	CbGpPWpGaD
Celecoxib—ALB—Metabolism—ITPR2—kidney cancer	4.05e-06	3.45e-05	CbGpPWpGaD
Celecoxib—MAPK14—Innate Immune System—MAPK1—kidney cancer	4.04e-06	3.44e-05	CbGpPWpGaD
Celecoxib—MAPK14—Signaling Pathways—IGF2—kidney cancer	4.03e-06	3.43e-05	CbGpPWpGaD
Celecoxib—MAPK14—Immune System—CDH1—kidney cancer	4.02e-06	3.43e-05	CbGpPWpGaD
Celecoxib—MAPK14—Signaling Pathways—CDKN2B—kidney cancer	4.01e-06	3.42e-05	CbGpPWpGaD
Celecoxib—CYP3A4—Metabolism—FH—kidney cancer	3.99e-06	3.4e-05	CbGpPWpGaD
Celecoxib—CYP3A4—Metabolism—APRT—kidney cancer	3.99e-06	3.4e-05	CbGpPWpGaD
Celecoxib—PTGS2—Metabolism—BCHE—kidney cancer	3.98e-06	3.39e-05	CbGpPWpGaD
Celecoxib—PDPK1—Disease—KRAS—kidney cancer	3.95e-06	3.36e-05	CbGpPWpGaD
Celecoxib—PDPK1—Immune System—PIK3CA—kidney cancer	3.93e-06	3.35e-05	CbGpPWpGaD
Celecoxib—PTGS2—Metabolism—SLC5A5—kidney cancer	3.93e-06	3.34e-05	CbGpPWpGaD
Celecoxib—PDPK1—Signaling Pathways—CDKN1B—kidney cancer	3.91e-06	3.33e-05	CbGpPWpGaD
Celecoxib—ALB—Platelet activation, signaling and aggregation—PIK3CA—kidney cancer	3.9e-06	3.32e-05	CbGpPWpGaD
Celecoxib—MAPK14—Signaling Pathways—IGF1R—kidney cancer	3.9e-06	3.32e-05	CbGpPWpGaD
Celecoxib—MAPK14—Hemostasis—PIK3CA—kidney cancer	3.89e-06	3.32e-05	CbGpPWpGaD
Celecoxib—PDPK1—Signaling Pathways—IL2—kidney cancer	3.83e-06	3.26e-05	CbGpPWpGaD
Celecoxib—MAPK14—Innate Immune System—KRAS—kidney cancer	3.82e-06	3.25e-05	CbGpPWpGaD
Celecoxib—PTGS2—Metabolism—SLC2A1—kidney cancer	3.79e-06	3.23e-05	CbGpPWpGaD
Celecoxib—MAPK14—Hemostasis—TP53—kidney cancer	3.77e-06	3.21e-05	CbGpPWpGaD
Celecoxib—CYP3A4—Metabolism—GPC3—kidney cancer	3.75e-06	3.19e-05	CbGpPWpGaD
Celecoxib—ALB—Metabolism of lipids and lipoproteins—POMC—kidney cancer	3.73e-06	3.18e-05	CbGpPWpGaD
Celecoxib—PDPK1—Signaling Pathways—CCND1—kidney cancer	3.73e-06	3.18e-05	CbGpPWpGaD
Celecoxib—PDPK1—Signaling Pathways—JUN—kidney cancer	3.72e-06	3.17e-05	CbGpPWpGaD
Celecoxib—CA9—Metabolism—PTEN—kidney cancer	3.71e-06	3.16e-05	CbGpPWpGaD
Celecoxib—PDPK1—Signaling Pathways—CTNNB1—kidney cancer	3.69e-06	3.15e-05	CbGpPWpGaD
Celecoxib—ALB—Metabolism—GSTT1—kidney cancer	3.69e-06	3.14e-05	CbGpPWpGaD
Celecoxib—ALB—Metabolism—ACHE—kidney cancer	3.69e-06	3.14e-05	CbGpPWpGaD
Celecoxib—PTGS2—Disease—CDKN2B—kidney cancer	3.66e-06	3.12e-05	CbGpPWpGaD
Celecoxib—CYP3A4—Metabolism—CA2—kidney cancer	3.65e-06	3.11e-05	CbGpPWpGaD
Celecoxib—PDPK1—Disease—PIK3CA—kidney cancer	3.63e-06	3.09e-05	CbGpPWpGaD
Celecoxib—PDPK1—Signaling Pathways—PTEN—kidney cancer	3.6e-06	3.07e-05	CbGpPWpGaD
Celecoxib—CYP2D6—Metabolism—CRABP1—kidney cancer	3.6e-06	3.06e-05	CbGpPWpGaD
Celecoxib—CYP2C9—Metabolism—CRABP1—kidney cancer	3.57e-06	3.04e-05	CbGpPWpGaD
Celecoxib—CYP3A4—Metabolism—ALAD—kidney cancer	3.56e-06	3.03e-05	CbGpPWpGaD
Celecoxib—MAPK14—Innate Immune System—PIK3CA—kidney cancer	3.51e-06	2.99e-05	CbGpPWpGaD
Celecoxib—ALB—Metabolism—SCARB1—kidney cancer	3.5e-06	2.98e-05	CbGpPWpGaD
Celecoxib—CYP3A4—Metabolism—ST3GAL2—kidney cancer	3.47e-06	2.96e-05	CbGpPWpGaD
Celecoxib—ALB—Metabolism—PTGS1—kidney cancer	3.46e-06	2.95e-05	CbGpPWpGaD
Celecoxib—MAPK14—Immune System—RAF1—kidney cancer	3.43e-06	2.92e-05	CbGpPWpGaD
Celecoxib—MAPK14—Immune System—RELA—kidney cancer	3.42e-06	2.91e-05	CbGpPWpGaD
Celecoxib—ALB—Metabolism—PSMD7—kidney cancer	3.39e-06	2.89e-05	CbGpPWpGaD
Celecoxib—MAPK14—Immune System—ERBB2—kidney cancer	3.39e-06	2.89e-05	CbGpPWpGaD
Celecoxib—CYP3A4—Metabolism—ALDH1A1—kidney cancer	3.39e-06	2.89e-05	CbGpPWpGaD
Celecoxib—ALB—Hemostasis—RAF1—kidney cancer	3.38e-06	2.88e-05	CbGpPWpGaD
Celecoxib—MAPK14—Immune System—MTOR—kidney cancer	3.35e-06	2.85e-05	CbGpPWpGaD
Celecoxib—CYP2D6—Metabolism—ITPR2—kidney cancer	3.34e-06	2.85e-05	CbGpPWpGaD
Celecoxib—MAPK14—Immune System—CD4—kidney cancer	3.34e-06	2.85e-05	CbGpPWpGaD
Celecoxib—CYP2C9—Metabolism—ITPR2—kidney cancer	3.31e-06	2.82e-05	CbGpPWpGaD
Celecoxib—CYP3A4—Metabolism—PGK1—kidney cancer	3.25e-06	2.77e-05	CbGpPWpGaD
Celecoxib—CYP3A4—Metabolism—SLC5A3—kidney cancer	3.25e-06	2.77e-05	CbGpPWpGaD
Celecoxib—PDPK1—Signaling Pathways—VEGFA—kidney cancer	3.25e-06	2.77e-05	CbGpPWpGaD
Celecoxib—CA4—Metabolism—PIK3CA—kidney cancer	3.24e-06	2.76e-05	CbGpPWpGaD
Celecoxib—ALB—Metabolism—BCHE—kidney cancer	3.22e-06	2.74e-05	CbGpPWpGaD
Celecoxib—PTGS2—Metabolism of lipids and lipoproteins—PTEN—kidney cancer	3.21e-06	2.73e-05	CbGpPWpGaD
Celecoxib—MAPK14—Signaling Pathways—HIF1A—kidney cancer	3.21e-06	2.73e-05	CbGpPWpGaD
Celecoxib—MAPK14—Signaling Pathways—TSC2—kidney cancer	3.2e-06	2.72e-05	CbGpPWpGaD
Celecoxib—CYP3A4—Metabolism—LDHB—kidney cancer	3.19e-06	2.72e-05	CbGpPWpGaD
Celecoxib—ALB—Metabolism—SLC5A5—kidney cancer	3.18e-06	2.71e-05	CbGpPWpGaD
Celecoxib—PTGS2—Metabolism—GSTP1—kidney cancer	3.16e-06	2.69e-05	CbGpPWpGaD
Celecoxib—MAPK14—Immune System—CDKN1B—kidney cancer	3.14e-06	2.68e-05	CbGpPWpGaD
Celecoxib—CA2—Metabolism—PIK3CA—kidney cancer	3.1e-06	2.64e-05	CbGpPWpGaD
Celecoxib—PDPK1—Signaling Pathways—MAPK3—kidney cancer	3.08e-06	2.62e-05	CbGpPWpGaD
Celecoxib—MAPK14—Immune System—IL2—kidney cancer	3.08e-06	2.62e-05	CbGpPWpGaD
Celecoxib—ALB—Metabolism—SLC2A1—kidney cancer	3.07e-06	2.61e-05	CbGpPWpGaD
Celecoxib—MAPK14—Signaling Pathways—KDR—kidney cancer	3.07e-06	2.61e-05	CbGpPWpGaD
Celecoxib—CYP2C9—Metabolism of lipids and lipoproteins—POMC—kidney cancer	3.06e-06	2.6e-05	CbGpPWpGaD
Celecoxib—CYP2D6—Metabolism—GSTT1—kidney cancer	3.05e-06	2.6e-05	CbGpPWpGaD
Celecoxib—CYP2D6—Metabolism—ACHE—kidney cancer	3.05e-06	2.6e-05	CbGpPWpGaD
Celecoxib—ALB—Hemostasis—IL2—kidney cancer	3.03e-06	2.58e-05	CbGpPWpGaD
Celecoxib—CYP2C9—Metabolism—ACHE—kidney cancer	3.02e-06	2.57e-05	CbGpPWpGaD
Celecoxib—CYP2C9—Metabolism—GSTT1—kidney cancer	3.02e-06	2.57e-05	CbGpPWpGaD
Celecoxib—PTGS2—Metabolism—ABCB1—kidney cancer	3e-06	2.55e-05	CbGpPWpGaD
Celecoxib—PDPK1—Signaling Pathways—MYC—kidney cancer	2.99e-06	2.55e-05	CbGpPWpGaD
Celecoxib—MAPK14—Immune System—JUN—kidney cancer	2.99e-06	2.55e-05	CbGpPWpGaD
Celecoxib—ALB—Metabolism of lipids and lipoproteins—PTGS2—kidney cancer	2.98e-06	2.54e-05	CbGpPWpGaD
Celecoxib—MAPK14—Immune System—CTNNB1—kidney cancer	2.97e-06	2.53e-05	CbGpPWpGaD
Celecoxib—PDPK1—Signaling Pathways—MAPK1—kidney cancer	2.93e-06	2.49e-05	CbGpPWpGaD
Celecoxib—ALB—Transmembrane transport of small molecules—RAF1—kidney cancer	2.93e-06	2.49e-05	CbGpPWpGaD
Celecoxib—PTGS2—Disease—HIF1A—kidney cancer	2.93e-06	2.49e-05	CbGpPWpGaD
Celecoxib—PTGS2—Disease—TSC2—kidney cancer	2.92e-06	2.49e-05	CbGpPWpGaD
Celecoxib—PTGS2—Metabolism—GSTM1—kidney cancer	2.91e-06	2.48e-05	CbGpPWpGaD
Celecoxib—MAPK14—Immune System—PTEN—kidney cancer	2.89e-06	2.46e-05	CbGpPWpGaD
Celecoxib—CYP2D6—Metabolism—SCARB1—kidney cancer	2.89e-06	2.46e-05	CbGpPWpGaD
Celecoxib—CYP2C9—Metabolism—SCARB1—kidney cancer	2.86e-06	2.44e-05	CbGpPWpGaD
Celecoxib—CYP2D6—Metabolism—PTGS1—kidney cancer	2.86e-06	2.43e-05	CbGpPWpGaD
Celecoxib—CYP2C9—Metabolism—PTGS1—kidney cancer	2.83e-06	2.41e-05	CbGpPWpGaD
Celecoxib—MAPK14—Signaling Pathways—KIT—kidney cancer	2.83e-06	2.41e-05	CbGpPWpGaD
Celecoxib—MAPK14—Signaling Pathways—APC—kidney cancer	2.83e-06	2.41e-05	CbGpPWpGaD
Celecoxib—CYP2D6—Metabolism—PSMD7—kidney cancer	2.8e-06	2.39e-05	CbGpPWpGaD
Celecoxib—CYP2C9—Metabolism—PSMD7—kidney cancer	2.78e-06	2.37e-05	CbGpPWpGaD
Celecoxib—CYP3A4—Metabolism—CA9—kidney cancer	2.77e-06	2.36e-05	CbGpPWpGaD
Celecoxib—PDPK1—Signaling Pathways—KRAS—kidney cancer	2.76e-06	2.35e-05	CbGpPWpGaD
Celecoxib—PTGS2—Metabolism—CYP1A1—kidney cancer	2.76e-06	2.35e-05	CbGpPWpGaD
Celecoxib—MAPK14—Signaling Pathways—POMC—kidney cancer	2.69e-06	2.29e-05	CbGpPWpGaD
Celecoxib—CYP2D6—Metabolism—BCHE—kidney cancer	2.66e-06	2.26e-05	CbGpPWpGaD
Celecoxib—MAPK14—Signaling Pathways—BRAF—kidney cancer	2.66e-06	2.26e-05	CbGpPWpGaD
Celecoxib—CYP2C9—Metabolism—BCHE—kidney cancer	2.63e-06	2.24e-05	CbGpPWpGaD
Celecoxib—CYP2D6—Metabolism—SLC5A5—kidney cancer	2.62e-06	2.23e-05	CbGpPWpGaD
Celecoxib—CA9—Metabolism—PIK3CA—kidney cancer	2.62e-06	2.23e-05	CbGpPWpGaD
Celecoxib—CYP2C9—Metabolism—SLC5A5—kidney cancer	2.6e-06	2.22e-05	CbGpPWpGaD
Celecoxib—ALB—Metabolism of lipids and lipoproteins—PTEN—kidney cancer	2.6e-06	2.21e-05	CbGpPWpGaD
Celecoxib—PTGS2—Disease—APC—kidney cancer	2.58e-06	2.2e-05	CbGpPWpGaD
Celecoxib—PTGS2—Disease—KIT—kidney cancer	2.58e-06	2.2e-05	CbGpPWpGaD
Celecoxib—ALB—Hemostasis—VEGFA—kidney cancer	2.58e-06	2.19e-05	CbGpPWpGaD
Celecoxib—ALB—Metabolism—GSTP1—kidney cancer	2.56e-06	2.18e-05	CbGpPWpGaD
Celecoxib—PDPK1—Signaling Pathways—PIK3CA—kidney cancer	2.54e-06	2.16e-05	CbGpPWpGaD
Celecoxib—CYP2D6—Metabolism—SLC2A1—kidney cancer	2.53e-06	2.16e-05	CbGpPWpGaD
Celecoxib—CYP2C9—Metabolism—SLC2A1—kidney cancer	2.51e-06	2.14e-05	CbGpPWpGaD
Celecoxib—MAPK14—Immune System—MAPK3—kidney cancer	2.47e-06	2.11e-05	CbGpPWpGaD
Celecoxib—MAPK14—Gene Expression—MAPK3—kidney cancer	2.46e-06	2.09e-05	CbGpPWpGaD
Celecoxib—PDPK1—Signaling Pathways—TP53—kidney cancer	2.46e-06	2.09e-05	CbGpPWpGaD
Celecoxib—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—kidney cancer	2.44e-06	2.08e-05	CbGpPWpGaD
Celecoxib—ALB—Hemostasis—MAPK3—kidney cancer	2.44e-06	2.08e-05	CbGpPWpGaD
Celecoxib—PTGS2—Disease—BRAF—kidney cancer	2.42e-06	2.06e-05	CbGpPWpGaD
Celecoxib—ALB—Metabolism—ABCB1—kidney cancer	2.42e-06	2.06e-05	CbGpPWpGaD
Celecoxib—MAPK14—Gene Expression—MYC—kidney cancer	2.39e-06	2.04e-05	CbGpPWpGaD
Celecoxib—MAPK14—Immune System—MAPK1—kidney cancer	2.35e-06	2e-05	CbGpPWpGaD
Celecoxib—ALB—Metabolism—GSTM1—kidney cancer	2.35e-06	2e-05	CbGpPWpGaD
Celecoxib—CYP3A4—Metabolism—CRABP1—kidney cancer	2.35e-06	2e-05	CbGpPWpGaD
Celecoxib—ALB—Hemostasis—MAPK1—kidney cancer	2.32e-06	1.97e-05	CbGpPWpGaD
Celecoxib—PTGS2—Metabolism of lipids and lipoproteins—PIK3CA—kidney cancer	2.26e-06	1.93e-05	CbGpPWpGaD
Celecoxib—ALB—Metabolism—CYP1A1—kidney cancer	2.23e-06	1.9e-05	CbGpPWpGaD
Celecoxib—MAPK14—Immune System—KRAS—kidney cancer	2.22e-06	1.89e-05	CbGpPWpGaD
Celecoxib—MAPK14—Signaling Pathways—RAF1—kidney cancer	2.22e-06	1.89e-05	CbGpPWpGaD
Celecoxib—MAPK14—Signaling Pathways—RELA—kidney cancer	2.21e-06	1.88e-05	CbGpPWpGaD
Celecoxib—MAPK14—Signaling Pathways—ERBB2—kidney cancer	2.19e-06	1.87e-05	CbGpPWpGaD
Celecoxib—ALB—Hemostasis—KRAS—kidney cancer	2.19e-06	1.87e-05	CbGpPWpGaD
Celecoxib—CYP3A4—Metabolism—ITPR2—kidney cancer	2.19e-06	1.86e-05	CbGpPWpGaD
Celecoxib—MAPK14—Signaling Pathways—MTOR—kidney cancer	2.17e-06	1.84e-05	CbGpPWpGaD
Celecoxib—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—kidney cancer	2.13e-06	1.81e-05	CbGpPWpGaD
Celecoxib—CYP2D6—Metabolism—GSTP1—kidney cancer	2.11e-06	1.8e-05	CbGpPWpGaD
Celecoxib—CYP2C9—Metabolism—GSTP1—kidney cancer	2.1e-06	1.78e-05	CbGpPWpGaD
Celecoxib—PTGS2—Metabolism—POMC—kidney cancer	2.06e-06	1.75e-05	CbGpPWpGaD
Celecoxib—MAPK14—Immune System—PIK3CA—kidney cancer	2.04e-06	1.74e-05	CbGpPWpGaD
Celecoxib—MAPK14—Signaling Pathways—CDKN1B—kidney cancer	2.03e-06	1.73e-05	CbGpPWpGaD
Celecoxib—PTGS2—Disease—RAF1—kidney cancer	2.02e-06	1.72e-05	CbGpPWpGaD
Celecoxib—ALB—Hemostasis—PIK3CA—kidney cancer	2.01e-06	1.71e-05	CbGpPWpGaD
Celecoxib—PTGS2—Disease—ERBB2—kidney cancer	2e-06	1.7e-05	CbGpPWpGaD
Celecoxib—CYP2D6—Metabolism—ABCB1—kidney cancer	2e-06	1.7e-05	CbGpPWpGaD
Celecoxib—CYP3A4—Metabolism—ACHE—kidney cancer	1.99e-06	1.7e-05	CbGpPWpGaD
Celecoxib—CYP3A4—Metabolism—GSTT1—kidney cancer	1.99e-06	1.7e-05	CbGpPWpGaD
Celecoxib—MAPK14—Signaling Pathways—IL2—kidney cancer	1.99e-06	1.69e-05	CbGpPWpGaD
Celecoxib—CYP2C9—Metabolism—ABCB1—kidney cancer	1.98e-06	1.69e-05	CbGpPWpGaD
Celecoxib—PTGS2—Disease—MTOR—kidney cancer	1.98e-06	1.68e-05	CbGpPWpGaD
Celecoxib—PTGS2—Disease—CD4—kidney cancer	1.97e-06	1.68e-05	CbGpPWpGaD
Celecoxib—ALB—Hemostasis—TP53—kidney cancer	1.95e-06	1.66e-05	CbGpPWpGaD
Celecoxib—CYP2D6—Metabolism—GSTM1—kidney cancer	1.94e-06	1.65e-05	CbGpPWpGaD
Celecoxib—MAPK14—Signaling Pathways—CCND1—kidney cancer	1.94e-06	1.65e-05	CbGpPWpGaD
Celecoxib—MAPK14—Signaling Pathways—JUN—kidney cancer	1.93e-06	1.65e-05	CbGpPWpGaD
Celecoxib—CYP2C9—Metabolism—GSTM1—kidney cancer	1.93e-06	1.64e-05	CbGpPWpGaD
Celecoxib—MAPK14—Signaling Pathways—CTNNB1—kidney cancer	1.92e-06	1.63e-05	CbGpPWpGaD
Celecoxib—CYP3A4—Metabolism—SCARB1—kidney cancer	1.89e-06	1.61e-05	CbGpPWpGaD
Celecoxib—MAPK14—Signaling Pathways—PTEN—kidney cancer	1.87e-06	1.59e-05	CbGpPWpGaD
Celecoxib—CYP3A4—Metabolism—PTGS1—kidney cancer	1.87e-06	1.59e-05	CbGpPWpGaD
Celecoxib—PTGS2—Disease—CDKN1B—kidney cancer	1.85e-06	1.58e-05	CbGpPWpGaD
Celecoxib—CYP2D6—Metabolism—CYP1A1—kidney cancer	1.84e-06	1.57e-05	CbGpPWpGaD
Celecoxib—ALB—Metabolism of lipids and lipoproteins—PIK3CA—kidney cancer	1.83e-06	1.56e-05	CbGpPWpGaD
Celecoxib—CYP3A4—Metabolism—PSMD7—kidney cancer	1.83e-06	1.56e-05	CbGpPWpGaD
Celecoxib—CYP2C9—Metabolism—CYP1A1—kidney cancer	1.83e-06	1.55e-05	CbGpPWpGaD
Celecoxib—PTGS2—Disease—CTNNB1—kidney cancer	1.75e-06	1.49e-05	CbGpPWpGaD
Celecoxib—CYP3A4—Metabolism—BCHE—kidney cancer	1.74e-06	1.48e-05	CbGpPWpGaD
Celecoxib—CYP3A4—Metabolism—SLC5A5—kidney cancer	1.72e-06	1.46e-05	CbGpPWpGaD
Celecoxib—PTGS2—Disease—PTEN—kidney cancer	1.71e-06	1.45e-05	CbGpPWpGaD
Celecoxib—MAPK14—Signaling Pathways—VEGFA—kidney cancer	1.69e-06	1.44e-05	CbGpPWpGaD
Celecoxib—ALB—Metabolism—POMC—kidney cancer	1.66e-06	1.42e-05	CbGpPWpGaD
Celecoxib—CYP3A4—Metabolism—SLC2A1—kidney cancer	1.66e-06	1.41e-05	CbGpPWpGaD
Celecoxib—MAPK14—Signaling Pathways—MAPK3—kidney cancer	1.6e-06	1.36e-05	CbGpPWpGaD
Celecoxib—MAPK14—Signaling Pathways—MYC—kidney cancer	1.55e-06	1.32e-05	CbGpPWpGaD
Celecoxib—MAPK14—Signaling Pathways—MAPK1—kidney cancer	1.52e-06	1.3e-05	CbGpPWpGaD
Celecoxib—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—kidney cancer	1.5e-06	1.28e-05	CbGpPWpGaD
Celecoxib—PTGS2—Disease—MAPK3—kidney cancer	1.46e-06	1.24e-05	CbGpPWpGaD
Celecoxib—MAPK14—Signaling Pathways—KRAS—kidney cancer	1.44e-06	1.22e-05	CbGpPWpGaD
Celecoxib—PTGS2—Metabolism—PTEN—kidney cancer	1.43e-06	1.22e-05	CbGpPWpGaD
Celecoxib—PTGS2—Disease—MYC—kidney cancer	1.42e-06	1.21e-05	CbGpPWpGaD
Celecoxib—PTGS2—Disease—MAPK1—kidney cancer	1.39e-06	1.18e-05	CbGpPWpGaD
Celecoxib—CYP3A4—Metabolism—GSTP1—kidney cancer	1.38e-06	1.18e-05	CbGpPWpGaD
Celecoxib—CYP2D6—Metabolism—POMC—kidney cancer	1.37e-06	1.17e-05	CbGpPWpGaD
Celecoxib—CYP2C9—Metabolism—POMC—kidney cancer	1.36e-06	1.16e-05	CbGpPWpGaD
Celecoxib—ALB—Metabolism—PTGS2—kidney cancer	1.33e-06	1.13e-05	CbGpPWpGaD
Celecoxib—MAPK14—Signaling Pathways—PIK3CA—kidney cancer	1.32e-06	1.12e-05	CbGpPWpGaD
Celecoxib—PTGS2—Disease—KRAS—kidney cancer	1.31e-06	1.12e-05	CbGpPWpGaD
Celecoxib—CYP3A4—Metabolism—ABCB1—kidney cancer	1.31e-06	1.11e-05	CbGpPWpGaD
Celecoxib—MAPK14—Signaling Pathways—TP53—kidney cancer	1.28e-06	1.09e-05	CbGpPWpGaD
Celecoxib—CYP3A4—Metabolism—GSTM1—kidney cancer	1.27e-06	1.08e-05	CbGpPWpGaD
Celecoxib—PTGS2—Disease—PIK3CA—kidney cancer	1.2e-06	1.03e-05	CbGpPWpGaD
Celecoxib—CYP3A4—Metabolism—CYP1A1—kidney cancer	1.2e-06	1.03e-05	CbGpPWpGaD
Celecoxib—ALB—Metabolism—PTEN—kidney cancer	1.16e-06	9.85e-06	CbGpPWpGaD
Celecoxib—CYP2D6—Metabolism—PTGS2—kidney cancer	1.09e-06	9.32e-06	CbGpPWpGaD
Celecoxib—CYP2C9—Metabolism—PTGS2—kidney cancer	1.09e-06	9.24e-06	CbGpPWpGaD
Celecoxib—PTGS2—Metabolism—PIK3CA—kidney cancer	1.01e-06	8.59e-06	CbGpPWpGaD
Celecoxib—CYP2D6—Metabolism—PTEN—kidney cancer	9.55e-07	8.13e-06	CbGpPWpGaD
Celecoxib—CYP2C9—Metabolism—PTEN—kidney cancer	9.47e-07	8.06e-06	CbGpPWpGaD
Celecoxib—CYP3A4—Metabolism—POMC—kidney cancer	8.98e-07	7.64e-06	CbGpPWpGaD
Celecoxib—ALB—Metabolism—PIK3CA—kidney cancer	8.16e-07	6.95e-06	CbGpPWpGaD
Celecoxib—CYP3A4—Metabolism—PTGS2—kidney cancer	7.16e-07	6.1e-06	CbGpPWpGaD
Celecoxib—CYP2D6—Metabolism—PIK3CA—kidney cancer	6.74e-07	5.74e-06	CbGpPWpGaD
Celecoxib—CYP2C9—Metabolism—PIK3CA—kidney cancer	6.68e-07	5.69e-06	CbGpPWpGaD
Celecoxib—CYP3A4—Metabolism—PTEN—kidney cancer	6.24e-07	5.32e-06	CbGpPWpGaD
Celecoxib—CYP3A4—Metabolism—PIK3CA—kidney cancer	4.4e-07	3.75e-06	CbGpPWpGaD
